We use our own and third-party cookies to optimize your experience on this site, including to maintain user sessions. Without these cookies our site will not function well. If you continue browsing our site we take that to mean that you understand and accept how we use the cookies. If you wish to decline our cookies we will redirect you to Google.
Already have an account? Sign in.

 Remember Me | Forgot Your Password?

Chr. Hansen Tests Effectiveness Of Probiotic Strain In Preventing Respiratory Infections

October 4, 2011: 08:01 PM EST
Chr. Hansen is launching a large-scale clinical study to “document the immune-boosting properties” of its probiotic strains. The company’s goal is to prove that consuming its proprietary probiotics will protect people from colds and influenza. The study will use an “influenza vaccination model” to test the impact of the company’s flagship probiotic strain, L. casei 431, on 1,058 healthy adults. The multi-center, randomized, placebo-controlled, parallel-group clinical study is recruiting participants through November. According to the company, about 500 million non-influenza-related viral respiratory tract infections occur each year in the U.S. alone.
"Unprecedented Large Scale Clinical Study to Further Document the Immune Boosting Properties of Chr. Hansen's Probiotics", Press release, Chr. Hansen, October 04, 2011, © Chr.Hansen
Vitality & Better Living
Companies, Organizations
Marketing & Advertising
Press Release
Products & Brands
Research, Studies, Advice
Developed by Yuri Ingultsov Software Lab.